State Street Corp Zynerba Pharmaceuticals, Inc. Transaction History

State Street Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$1.83 - $3.02 $18,854 - $31,115	10,303 Added 9.41%	119,741 $245,000
Q2 2021 Aug 16, 2021	BUY	$3.83 - $5.98 $374,719 - $585,071	97,838 Added 843.43%	109,438 $579,000
Q1 2021 May 17, 2021	BUY	$3.33 - $8.76 $38,628 - $101,616	11,600 New	11,600 $54,000
Q3 2020 Nov 10, 2020	SELL	$3.23 - $4.3 $75,097 - $99,975	-23,250 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$3.31 - $6.54 $1.33 Million - $2.63 Million	-401,475 Reduced 94.53%	23,250 $78,000
Q1 2020 May 11, 2020	BUY	$2.9 - $6.16 $1.23 Million - $2.62 Million	424,725 New	424,725 $1.63 Million

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.